With a rapidly aging population, it is as important as ever to conduct Alzheimer’s disease clinical trials in the quest to usher in next generation treatments and hopefully improve the incredibly difficult objective of diagnosing the disease. MD Magazine® recently interviewed Arjun Masurkar, MD, PhD, a neurologist and assistant professor in the departments of neurology and neuroscience and psychology at NYU Langone Health.
The Importance of with Many Clinical Trials
There are far more cancer-based clinical trials than in the Alzheimer’s field, and to progress treatments, we will need many more of the latter. The total number of patient participants needs to increase, including a diversification of participants.
Funding of Studies
Absolutely critical—funding should come from government, from the NIH, foundations and industry. Generally speaking, the more funding that is put into a therapeutic area the more beneficial the outcomes, over time.
Arjun Masurkar, MD, PhD, a neurologist and assistant professor in the departments of neurology and neuroscience and psychology at NYU Langone Health
Call to Action: Dr. Masurkar is a global expert in Alzheimer’s disease. If you live in the New York area and have a loved one with an Alzheimer’s disease diagnosis, it may make sense to contact him.